Sector News

Stryker CEO says he remains focused on acquisitions

January 29, 2015
Life sciences
(Reuters) – The chief executive officer of U.S. medical device maker Stryker Corp (SYK.N), recently rumored to have been preparing a bid for British rival Smith & Nephew Plc (SN.L), said on Tuesday that acquisitions are his top priority for spending cash, but he gave no hint that any sort of deal was imminent.
 
The timing of acquisitions is unpredictable, Stryker Chief Executive Officer Kevin Lobo said on the company’s fourth-quarter earnings conference call.
 
“Right now we are pursuing the acquisition deal flow, and we’ll see what happens,” Lobo said. “We do plan to put our money to work.”Rumors that Stryker could bid soon for fellow orthopedic implant maker Smith & Nephew, frequently named as a possible takeover candidate, surfaced late last month.
 
Smith & Nephew CEO Olivier Bohuon, speaking earlier this month at an investor conference, said the company had not decided to follow other medical device makers that are bulking up through mergers.
 
Years of slow growth and persistent price erosion have prompted some large mergers in the orthopedic implant sector, with Johnson & Johnson (JNJ.N) buying Swiss device maker Synthes for about $21 billion in 2012, and Zimmer Holdings Inc (ZMH.N) in the process of acquiring privately held Biomet for $13.4 billion.
 
Stryker itself has been active in acquiring smaller companies, including its $1.65 billion deal for Mako Surgical Corp in 2013.
 
The Kalamazoo, Michigan-based maker of artificial hips and knees and other hospital supplies said on Tuesday its fourth-quarter net earnings fell 33 percent to $260 million, or 67 cents a share, hurt by charges for product recalls and costs related to opening a regional headquarters in Europe.
 
The company earned $386 million, or $1.01 a share, a year ago. Sales rose 6.1 percent to $2.62 billion in the latest quarter.
 
(Reporting by Susan Kelly in Chicago. Editing by Andre Grenon)

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.